Cassava Sciences, Inc. (SAVA, Financial) has revealed a leadership transition following the retirement of James Kupiec, the company's Chief Medical Officer, which took effect on May 9. The company expressed its gratitude for Kupiec's contributions during his tenure.
In conjunction with this transition, Cassava Sciences has appointed Jack Moore to the position of Senior Vice President of Clinical Development. Moore will be reporting directly to Rick Barry, the CEO of Cassava Sciences, as he assumes his new responsibilities. This appointment is part of the company's strategic efforts to strengthen its clinical development initiatives.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Cassava Sciences Inc (SAVA, Financial) is $2.00 with a high estimate of $2.00 and a low estimate of $2.00. The average target implies an upside of 36.99% from the current price of $1.46. More detailed estimate data can be found on the Cassava Sciences Inc (SAVA) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Cassava Sciences Inc's (SAVA, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
